$43.140
+0.375 (+0.87%)收盤時
TRAX 同業比較
In the context of the broader market, TRAX competes directly with industry leaders such as KARD and TYRA. With a market capitalization of $1.48B, it holds a leading position in the sector. When comparing efficiency, TRAX's gross margin of N/A stands against KARD's N/A and TYRA's N/A. Such benchmarking helps identify whether First Tracks Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.
First Tracks Biotherapeutics Inc 財務表現
The company has experienced significant losses, with a net income of -33,374,000 USD in Q2 2026 and an EPS of -0.95. However, the current ratio has improved to 14.28, indicating better liquidity.
Financials
FY2026Q2
YoY:
-23.88%
-34.94M
Operating Profit
FY2026Q2
YoY:
-21.37%
-33.37M
Net Income after Tax
FY2026Q2
YoY:
-22.13%
-0.95
EPS - Diluted
FY2026Q2
YoY:
-17.41%
-31.94M
Free Cash Flow
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。